Kornimate/medical-research-clean huggingface dataset:
instant message-guided hypertension management intervention among stroke survivors

Conditions: Stroke; Hypertension; Lifestyle Modifications

Summary: this pilot and feasibility study aims to develop an automated instant message-delivered intervention (i.e., emi) for hypertension management in stroke survivors, and to investigate the feasibility and effectiveness of the intervention.

intervention group: participants in intervention group will receive the emi for 4 weeks. based on the steps of mobile message development recommended by abroms, et al., we will develop a message content library and protocol for emi delivery. 1. message contents: the message content library will consist of two parts: 1. brief stroke and hypertension education messages (mandatory), and 2. lifestyle modification messages (optional). 2. message delivery * regular messages: the messages in the two parts will be sent regularly to each participant. as personalisation is a core process subject to behavioural changes, the content, frequency, and timing of the messages will be determined based on participants' preferences. to save labour and increase efficiency, we will develop a message 'scheduler' program. we will pre-set the message scheduler, which will then automatically send out content to participants according to their preferences. the development of the program is highly useful particularly in cases which participants prefer to receive messages during non-office hours. * nurse-led real-time support messages (chat-type): chat-based nurse support will be given to the participants as an extension of the regular messages. however, the participants will be informed beforehand that the nurse will only play a supportive role and will not provide formal care. the number of the chat messages will not be limited, but the nurse-led real-time support messages will only be provided during working hours (i.e., 9am-6pm) on weekdays to limit the nurse ra's workload. control group: the control group will receive one instant message about general stroke management including hypertension management from the hospital authority of hk sar government website (https://www21.ha.org.hk/smartpatient/spw/en-us/disease-information/disease/?guid=29ac1219-3d68-4378-a2bd-09e111da3650), which is open to the public.

Eligibility criteria:
inclusion criteria: * diagnosis of stroke (icd-10 codes: i60-i69) * diagnosis of hypertension and antihypertension medication * aged ≥18 * able to read and communicate in chinese (cantonese or putonghua) * able to use text messaging function on mobile phones * moca 5-minute protocol (cognitive screen) ≥14 (equivalence to mmse ≥ 21) exclusion criteria: * currently receiving active stroke care in acute or post-acute inpatient settings * has diagnosis of psychiatric disease or is currently taking psychotropic drug

Keywords: stroke hypertension management
medico-economical evaluation on buccodental teleexpertise in nursing home

Conditions: Tooth Diseases

Summary: oral care in medical and social institutions is a real public health problem. the impact of poor oral health on the general state of residents but also on their overall quality of life is significant. the development of a precise regulatory framework for telemedicine in france aims to transform experiments into sustainable medical activities. odontology often set aside in this reflection, must be reintegrated. the use of tele-expertise for the oral care of nursing home residents should make it possible to replace oral health in medico-social institutions. the investigators will assess in a cluster randomized controlled study whether the buccodental telemedicine has a viable economic model and a significant impact on the overall health of facility for dependent elderly persons residents. the medico-economic impact of the buccodental telexpertise is fundamental for the development of this innovative activity.


Eligibility criteria:
inclusion criteria: * be resident of a facility for dependent elderly persons involved in the study * have given their free, informed and signed consent * beneficiary or member of a social security scheme exclusion criteria: * incapacity to open the mouth * contrary opinion of the medical team (end of life) * change of nursing home planned within 6 months * subject in a period of relative exclusion from another protocol * subject's participation in another study * subject deprived of liberty by judicial or administrative decision

Keywords: telemedicine dentistry long-term-care-home
early pp monitored by eit in patients with ards

Conditions: Acute Respiratory Distress Syndrome

Summary: acute respiratory distress syndrome (ards) is a syndrome characterized by respiratory distress and refractory hypoxemia caused by pulmonary and extra-pulmonary factors. despite improvements in diagnosis and treatment in recent years, the mortality rate of severe ards is still around 40%. the distribution of lung lesions in ards patients is significantly gravity-dependent. even with lung-protective ventilation strategies, tidal volume is concentrated in the ventral lung region, leading to ventilator-associated lung injury. prone position ventilation can increase ventilation to the dorsal lung tissue and improve the ventilation-perfusion ratio, thus improving oxygenation. during prone position ventilation in ards patients, lung-protective ventilation strategies should be maintained, but with different respiratory mechanics from the supine position, requiring adjustment of ventilator parameters. electrical impedance tomography (eit) technology can be used for bedside monitoring of mechanically ventilated patients, providing real-time feedback on the patient's ventilation status and having great potential for clinical applications. investigators believes that eit monitoring during prone position ventilation in ards patients can individualize lung-protective ventilation strategies, minimize alveolar overdistension and collapse, improve the weaning success rate of invasive ventilation, and ultimately improve patient prognosis.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old； 2. meets the diagnostic criteria for ards according to the 2012 berlin definition； 3. intubation with invasive mechanical ventilation time \< 36 hours； 4. pao2/fio2 \< 150mmhg. exclusion criteria: 1. contraindication to the prone position; 2. contraindication to the eit; 3. patients have received extracorporeal membrane oxygenation treatment.

Keywords: acute respiratory distress syndrome, prone position, electrical impedance tomography, mechanical ventilation
the effect of long-term use of bisphosphonates on femur morphology

Conditions: Osteoporosis; Knee Osteoarthristis

Summary: recent studies have shown that bone modeling can occur throughout life, suggesting bone has a persistent ability of adapting structure to loading. some bone medications have a significant effect on the process of bone modeling based on histological studies. bisphosphonates (bp), a classical anti-resorption drug which impacts the process of bone turnover, is related with atypical femur fractures while the mechanism is unclear. several hypotheses are considered competitive. among them, increased femur bowing is associated with atypical femoral fractures. however, it remains doubtful whether long-term bp use increases femur bowing. thus, the investigators design this retrospective cohort study.

if the participants meet the inclusion criteria, the investigators will collect the baseline characteristics of patients including age, gender, body mass index (bmi), as well as characteristics of bmd by dual-energy x-ray absorptiometry (dxa), bp treatment (type of drugs, duration before baseline). the primary outcome was femoral lateral bowing (flb), femoral neck shaft angle (fnsa), and hip knee shaft angle (hksa) from the frontal plane in standing radiographs of the lower limbs.

Eligibility criteria:
inclusion criteria: * standing radiographs of the lower limb exclusion criteria: * non-standard lower limbs x-ray , rheumatoid arthritis, tumor of the femur， congenital anomalies of the lower extremity

Keywords: bisphosphonates atypical femur fracture
immunotherapy in subjects with hpv-6 associated aerodigestive precancerous lesions and malignancies

Conditions: Aerodigestive Precancerous Lesions and Malignancies

Summary: this is a phase i, open-label study to evaluate the safety, tolerability, and immunogenicity of ino-3106 alone or in combination with ino-9012 dna vaccines delivered by electroporation to subjects with hpv6 associated aerodigestive precancerous lesions and malignancies.

this is a phase i, open-label, study to evaluate the safety, tolerability, and immunogenicity of 3 mg or 6 mg ino-3106 alone or in combination with 1 mg of ino-9012 (dna plasmid encoding human interleukin 12) delivered by electroporation (ep) in subjects with hpv6 associated aerodigestive precancerous lesions and malignancies. subjects will be enrolled in 2 cohorts (3 subjects in each cohort): cohort i: first 3 subjects will be enrolled sequentially and will receive ino-3106 alone or in combination with ino-9012. cohort ii: the next 3 subjects will be treated with 6 mg of ino-3106 and 1 mg of ino-9012, or at the mtd (maximum tolerated dose) determined in cohort i.

Eligibility criteria:
inclusion criteria: * signed and dated written ethics committee approved informed consent * age ≥18 years * histologically documented hpv-6 positive aerodigestive invasive malignancy (mucosal squamous cell head and neck cancer or lung cancer) who have completed therapies such as radiation/chemoradiation/chemotherapy; or * histologically documented hpv-6 positive papilloma or hpv-6 related premalignant lesion (i.e., carcinoma in situ) in aerodigestive or head and neck regions. * prior to study entry, subjects will have exhausted all treatments that are/have been used in these indications which may include any combination of surgery, anti-viral therapy, chemotherapy and/or radiation therapy. * core biopsy must be obtained prior to enrollment to confirm invasive cancer. archival material is allowed. * adequate bone marrow, hepatic, and renal function. anc (absolute neutrophil count) ≥ 1.5x109 cell/ml, platelets ≥75,000 cells/mm3, hemoglobin ≥ 9.0 g/dl, concentrations of total serum bilirubin within 1.5 x upper limit of normal (uln), ast, alt within 2.5x uln, cpk within 2.5 x uln, serum creatinine ≤ 1.5x uln * ecog (eastern cooperative oncology group) performance status of 0-2 exclusion criteria: * participation in a clinical trial within 30 days before entry * any cardiac pre-excitation syndromes, e.g. wolff-parkinson-white syndrome * presence of metal implants within 5 cm of the planned site(s) of injection * anticipated concomitant immunosuppressive therapy (excluding non-systemic inhaled, topical skin and/or eye drop-containing corticosteroids) * administration of any vaccine within 6 weeks of enrollment

Keywords: aerodigestive lesions and malignancies human papillomavirus squamous cell carcinoma
study of teriparatide (forteo) to treat adults with osteogenesis imperfecta

Conditions: Osteogenesis Imperfecta

Summary: the purpose of this study is to determine the effectiveness of teriparatide (forteo), which is human parathyroid hormone 1-34, for increasing bone mass and improving bone structure in adults affected with osteogenesis imperfecta (oi).

the purpose of this study is to determine the effectiveness of teriparatide (forteo), which is human parathyroid hormone 1-34, for increasing bone mass and improving bone structure in adults affected with osteogenesis imperfecta (oi). osteogenesis imperfecta is an inherited disorder of type i collagen, a major component of bones, and is characterized by multiple fractures and deformities. oi affects approximately 1-2 of every 10,000 individuals. virtually all of the studies of potential treatments for oi have evaluated the effects of medications only on children with oi. there is no cure for osteogenesis imperfecta and there is no established medical therapy for adults with the disorder. there are very limited data concerning the usefulness of parathyroid hormone therapy in oi. an effective anabolic therapy for the treatment of adult patients with oi could be a valuable asset to the affected patients. in this study, the working hypothesis is that individuals affected with oi who are treated with forteo will experience increased spine and hip bone mineral density and an increase in bone strength. although forteo is not expected to change the defect in the collagen produced, but is postulated to increase the quantity of bone formed and improve bone strength. this will be a placebo controlled, double blinded trial; half the patients will receive forteo 20 ug/day sq. adult patients (age at least 18 yrs) with oi will be enrolled for a treatment duration of 18 months. blood, urine, and bone density/strength tests will be done during the study to assess efficacy and safety.

Eligibility criteria:
inclusion criteria: * previous established diagnosis of osteogenesis imperfecta and * \> 2 previous adult fractures, and/or * bmd at lumbar spine, femoral neck or total hip t score \< -2.0 exclusion criteria: * open epiphyses. * history of external beam radiation to the skeleton. * pagets disease. * bone metastases or skeletal malignancies. * total lifetime exposure to any antiresorptive medication \< 90 days (primary inclusion). * treatment with any antiresorptive medication 12 months proceeding enrollment - (secondary inclusion). * women with oi who are pregnant or unwilling to use 1 form of contraception. * vitamin d insufficiency (25-hydroxyvitamin d \<15ng/ml)

Keywords: osteogenesis imperfecta brittle bone disease fragility fractures
study to assess the safety and effects of cells injected intravitreal in dry macular degeneration

Conditions: Dry Macular Degeneration

Summary: this will be an open-label, non-randomized multi-center study of adipose stem cell (asc) implantation. ascs will be derived from the patient's adipose or fat. liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. the cells will be delivered via needle injection into the eye.


Eligibility criteria:
inclusion criteria: * males and females between age 50 and 90 years * patients with dry amd * visual acuity in the study eye \<20200 (equal to or worse than 20/200) exclusion criteria: * females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study * inability to undergo syringe liposuction procedure or have any medical problems that contraindicate the procedure. * life expectancy \< 6 months due to concomitant illnesses. * vitrectomized eyes * exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study. * active infectious disease. . if patients have tested positive for hiv, htlv, hbv, hcv, cmv (igm \> igg) and/or syphilis, an expert will be consulted as to patient eligibility based on the patient's infectious status * any illness which might affect a patient's survival over the follow-up period * any illness which, in the investigator's judgement, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results * patients on chronic immunosuppressive transplant therapy * patients with severe coagulation disorders * systolic blood pressure (supine) ≤90 mmhg; * resting heart rate \> 100 bpm; * active clinical infection being treated by antibiotics within one week of enrollment. * cerebrovascular accident within 6 months prior to study entry * known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate. * severe copd or severe asthma that would contraindicate surgery * history of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last two years. * unwilling and/or not able to give written informed consent.

Keywords: macular degeneration stem cells adipose stem cells
new antibiotic to treat patients with community-acquired pneumonia due to a specific bacteria (s. pneumoniae pneumonia)

Conditions: Pneumonia, Pneumococcal; Community Acquired Infections; Gram-positive Bacterial Infections

Summary: this study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (s. pneumoniae)


Eligibility criteria:
other specific inclusion/exclusion criteria may apply. in order to determine eligibility, further examination by the investigator is necessary. inclusion criteria: * patients must have the signs and symptoms of pneumonia, with a chest xray showing a pneumonia. * the patient must have s. pneumoniae (a specific bacteria) growing in sputum or blood to continue treatment. exclusion criteria: * patients cannot have taken more than one day of another antibiotic before entering this study. * patients with hiv and a low cd4 count are excluded.

Keywords: pharmacia
sarcopenia and outcomes of neuroplasty in lumbar spinal stenosis

Conditions: Lumbar Spinal Stenosis; Neurogenic Claudication; Sarcopenia

Summary: the aim of the present study is to find out the influence of sarcopenia on outcomes of neuroplasty in patients with lumbar spinal stenosis.

frailty is an aging-related syndrome of physiological decline and correlated with sarcopenia. furthermore, lumbar spinal stenosis is a common disease in the old population and a neuroplasty is widely used to treat these patients. we postulate that the sarcopenia may be associated with the outcome of neuroplasty in patients with lumbar spinal stenosis, and there is no study about this topic as far as we know. to evaluate this association, we will use the criteria for sarcopenia which is made by asian working group for sarcopenia in 2019 in this study. we will compare the outcome of neuroplasty in patients with sarcopenia and without sarcopenia using several tools such as numeric rating scale (nrs), oswestry disability index (odi), and global perceived effect (gpe) score up to 6 months after the procedure.

Eligibility criteria:
inclusion criteria: * presence of lumbar spinal stenosis on mri * 65 ≤ age \<79 * neurogenic claudication due to spinal stenosis * chronic pain above than 3 months despite conservative therapies * scheduled for neuroplasty with racz catheter exclusion criteria: * allergy to local anesthetics, contrast dye, or steroid * use of anticoagulants or antiplatelet medication * coagulopathy or infection at the insertion site * neurological or psychiatric disorders * hemodynamic instability due to other underlying disorders * prior spine instrumentation * vascular claudication * refusal to participate in the study

Keywords: sarcopenia frailty lumbar spinal stenosis neurogenic claudication neuroplasty
the use of aromatherapy for symptom management

Conditions: Nausea, Vomiting and Anxiety Associated With Medical Oncology Patients

Summary: the purpose of this pilot study is to introduce the use of aromatherapy/essential oils to medical oncology patients at central dupage hospital to assess their perceived effectiveness to relieve symptoms of nausea or vomiting and/or anxiety. peppermint oil will be used for nausea/vomiting and lavender oil will be used for anxiety. this study will involve administration of aromatherapy to a convenience sample of patients, who will then be asked to complete a brief questionnaire. the questionnaire will involve a simple likert scale to measure efficacy (in the opinion of the patient) and simple multiple-choice questions to determine patients' likeliness to use aromatherapy again.


Eligibility criteria:
inclusion criteria: * adult hospitalized medical oncology patients admitted to central dupage hospital. * age 18 years or greater. * able to understand and speak english. * women of non-childbearing potential or with childbearing potential with a negative pregnancy test documented during the hospital stay. * able to understand concept of aromatherapy for treatment of distressing symptoms. exclusion criteria: * prisoners. * non-english speaking patients. * under the age of 18. * unable to comprehend the concept of aromatherapy. * severe cognitive impairment. * not experiencing the symptoms of nausea, vomiting or anxiety. * women with child-bearing potential who have not had a negative pregnancy test during the hospital stay. * patients with known allergy to lavender or peppermint.
feasibility of switching fluoropyrimidine due to cardiotoxicity study

Conditions: Solid Tumor

Summary: the purpose of the present study is to evaluate cardiotoxicity during re-challenge of a different modality of fluoropyrimidine (primary end-point s-1 and secondary any other fluoropyrimidine) after having perceived cardiotoxicity with a fluoropyrimidine based regimen previously. the patient population is being treated for solid tumors.

fluoropyrimidine chemotherapy agents, such as 5-fluorouracil and capecitabine, are occasionally associated with cardiotoxicity that may manifest as chest pain, ecg alterations, cardiac arrhythmia, and rarely myocardial infarction and sudden death. clinical fluoropyrimidine cardiotoxicity is infrequent (1-8% of patients), but subclinical toxicity may be much more common (up to one third of patients). the underlying mechanisms are not well understood, but they may include abnormal coronary artery contractility or spasm, and myocardial toxicity. cardiotoxicity may be less frequent with s-1 (a combination of tegafur, gimeracil and oteracil at a molar ratio of 1:0.4:1) as compared with 5-fluorouracil and capecitabine, but head-to-head comparisons are lacking. anecdotal evidence suggests that patients who have cardiotoxicity on other fluoropyrimidines may be successfully treated with s-1. the purpose of this retrospective study is to compare different 5-fluorouracil-based dosing modalities and s-1, and compare cardiotoxicity during these treatments. the patient population was treated for solid tumors with a 5-fluorouracil based regimen and had a cardiac event grade 1-4. all patients were re-challenged with a different fluoropyrimidine or s-1 and assessed for cardiotoxicity during re-challenge.

Eligibility criteria:
inclusion criteria: * solid tumor * cardiotoxicity grade 1-4 during fluoropyrimidine-based treatment * re-challenge with a different fluoropyrimidine-based therapy exclusion criteria: • participation in a trial with experimental drugs
body image, self-stigma, intuitive eating and exercise behavior in overweight and obese

Conditions: Overweight and Obesity

Summary: this study, it was aimed to investigate the relationship between body image, self-stigma, intuitive eating and exercise attitude levels, which are thought to be effective on the mental well-being of overweight and obese individuals. for this purpose, the body image scale, intuitive eating scale-2, exercise stages of change scale-short form and decisional balance scale in exercise will be used to assess overweight and obese individuals. 100 people will be included in the study.


Eligibility criteria:
inclusion criteria: * individuals aged between 18-65 * bmi ≥30 kg/m2, * no surgical operation in the last 6 months exclusion criteria: * musculoskeletal disorders or systemic diseases that may prevent exercise * the presence of psychiatric or neurological disease affecting cooperation and cognitive functions * presence of acute pain * heart pain * presence of previous myocardial infarction, subjective heart failure, uncontrolled diabetes and hypertension

Keywords: intuitive eating body image self-stigma exercise behavior overweight and obesity